These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

Compared to another common class of kidney medications, called DPP4is, GLP1-RA medications did better in helping slow the ...

A latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...

to ensure that they are ready to seek out and commit to GLP-1 therapy — and continue to have the emotional, mental, and even socioeconomic capacity to stay on medication for the long haul.

Study finds that a significant proportion of adults prescribed GLP-1 RAs for weight management discontinue treatment within a ...

While Novo Nordisk and rival obesity therapy manufacturer Eli Lilly are ... not comply with the FDA's regulations. The price of GLP-1 drugs has attracted the scrutiny of lawmakers, and Novo ...